Bo Yang1, Christina DeBenedictus2, Tessa Watt3, Sean Farley4, Alona Salita5, Whitney Hornsby6, Xiaoting Wu3, Morley Herbert7, Donald S Likosky3, Steven F Bolling3. 1. Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, Mich. Electronic address: boya@med.umich.edu. 2. University of Michigan Medical School, Ann Arbor, Mich. 3. Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, Mich. 4. College of Human Medicine, Michigan State University, East Lansing, Mich. 5. College of Osteopathic Medicine, Michigan State University, East Lansing, Mich. 6. Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Mich. 7. Southwest Data Consultants, Dallas, Tex.
Abstract
OBJECTIVES: To provide initial evidence on the management of mitral stenosis and pulmonary hypertension (PH) based on short-term and long-term outcomes following mitral valve surgery. METHODS: Consecutive patients with mitral stenosis (n = 317) who had undergone mitral valve surgery between 1992 and 2014 with recorded pulmonary artery pressure (PAP) data were reviewed. PH severity, based on systolic PAP, was categorized as mild (35 to 44 mm Hg), moderate (45 to 59 mm Hg), or severe (>60 mm Hg). Primary outcomes were 30-day mortality and long-term survival. RESULTS: There were no significant between-group differences in age or preoperative comorbidities. Mitral valve surgery included mitral valve replacement (78%) and repair (22%). The severe PH group had more mitral valve replacement (81%; P = .04), severe tricuspid valve regurgitation (31%; P = .003), right heart failure (17%; P = .02), and concomitant tricuspid valve procedures (46%; P < .001). For severe PH, 30-day mortality was 9%, with no significant group differences. Ten- and 12-year survival were significantly worse in the moderate-severe PH group (58% and 51%, respectively) compared with the normal PAP-mild PH group (83% and 79%, respectively) with a hazard ratio of 2.98 (95% confidence interval, 1.55-5.75; P = .001). Ten-year survival after mitral valve surgery for mitral stenosis was inversely associated with preoperative PAP. CONCLUSIONS: Mitral valve surgery can be performed with acceptable 30-day mortality for patients with mitral stenosis and moderate to severe PH, but long-term survival is impaired by moderate to severe PH. Patients with mitral stenosis and mild PH (systolic PAP 35-44 mm Hg) should be considered for mitral valve surgery.
OBJECTIVES: To provide initial evidence on the management of mitral stenosis and pulmonary hypertension (PH) based on short-term and long-term outcomes following mitral valve surgery. METHODS: Consecutive patients with mitral stenosis (n = 317) who had undergone mitral valve surgery between 1992 and 2014 with recorded pulmonary artery pressure (PAP) data were reviewed. PH severity, based on systolic PAP, was categorized as mild (35 to 44 mm Hg), moderate (45 to 59 mm Hg), or severe (>60 mm Hg). Primary outcomes were 30-day mortality and long-term survival. RESULTS: There were no significant between-group differences in age or preoperative comorbidities. Mitral valve surgery included mitral valve replacement (78%) and repair (22%). The severe PH group had more mitral valve replacement (81%; P = .04), severe tricuspid valve regurgitation (31%; P = .003), right heart failure (17%; P = .02), and concomitant tricuspid valve procedures (46%; P < .001). For severe PH, 30-day mortality was 9%, with no significant group differences. Ten- and 12-year survival were significantly worse in the moderate-severe PH group (58% and 51%, respectively) compared with the normal PAP-mild PH group (83% and 79%, respectively) with a hazard ratio of 2.98 (95% confidence interval, 1.55-5.75; P = .001). Ten-year survival after mitral valve surgery for mitral stenosis was inversely associated with preoperative PAP. CONCLUSIONS: Mitral valve surgery can be performed with acceptable 30-day mortality for patients with mitral stenosis and moderate to severe PH, but long-term survival is impaired by moderate to severe PH. Patients with mitral stenosis and mild PH (systolic PAP 35-44 mm Hg) should be considered for mitral valve surgery.
Authors: Bo Yang; Elizabeth L Norton; Reilly Hobbs; Linda Farhat; Xiaoting Wu; Whitney E Hornsby; Karen M Kim; Himanshu J Patel; G Michael Deeb Journal: J Thorac Cardiovasc Surg Date: 2018-12-21 Impact factor: 5.209
Authors: Bo Yang; Elizabeth L Norton; Terry Shih; Linda Farhat; Xiaoting Wu; Whitney E Hornsby; Karen M Kim; Himanshu J Patel; G Michael Deeb Journal: J Thorac Cardiovasc Surg Date: 2018-11-14 Impact factor: 5.209
Authors: Nicholas Collins; Stuart Sugito; Allan Davies; Andrew Boyle; Aaron Sverdlov; John Attia; Simon Stewart; David Playford; Geoff Strange Journal: Pulm Circ Date: 2022-10-01 Impact factor: 2.886
Authors: Michael V Genuardi; Daniel Shpilsky; Adam Handen; Gabrielle VanSpeybroeck; Ann Canterbury; Michael Lu; Kayle Shapero; Ricardo A Nieves; Floyd Thoma; Suresh R Mulukutla; João L Cavalcante; Stephen Y Chan Journal: J Am Heart Assoc Date: 2021-02-18 Impact factor: 5.501
Authors: Whitney E Hornsby; Elizabeth L Norton; Samantha Fink; Sara Saberi; Xiaoting Wu; Cheri L McGowan; Robert D Brook; Lee W Jones; Cristen J Willer; Himanshu J Patel; Kim A Eagle; Carl J Lavie; Melvyn Rubenfire; Bo Yang Journal: J Cardiopulm Rehabil Prev Date: 2020-03 Impact factor: 3.646
Authors: Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli Journal: Front Cardiovasc Med Date: 2018-05-23
Authors: Kyu-Yong Ko; Iksung Cho; Subin Kim; Yeonchan Seong; Dae-Young Kim; Ji Won Seo; Seng Chan You; Chi Young Shim; Geu-Ru Hong; Jong-Won Ha Journal: J Am Heart Assoc Date: 2022-07-29 Impact factor: 6.106